POST Online Media Lite Edition


Roche enters into definitive merger agreement to acquire Spark Therapeutics

Staff Writer |
Roche and Spark Therapeutics announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction.

Article continues below

This corresponds to a total transaction value of approximately US$ 4.3 billion on a fully diluted basis.

This price represents a premium of approximately 122% to Spark Therapeutics’ closing price on 22 February 2019 and a premium of approximately 19% to Spark Therapeutics’ 52 week high share price on 9 July 2018. The merger agreement has been unanimously approved by the boards of Spark Therapeutics and Roche.

Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all outstanding shares of Spark Therapeutics common stock, and Spark Therapeutics will file a recommendation statement containing the unanimous recommendation of the Spark Therapeutics board that Spark Therapeutics’ shareholders tender their shares to Roche.

Spark Therapeutics, based in Philadelphia, Pennsylvania, is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including blindness, haemophilia, lysosomal storage disorders and neurodegenerative diseases.

What to read next

Autodesk announces $100 million 3D investment fund
New Zealand rejects Huawei's first 5G bid citing national security risk
Roche and Ignyta reach definitive $1.7 billion merger agreement